Articles from AskBio Inc. (AskBio)

AskBio Announces FDA Acceptance of Investigational New Drug (IND) Application for AB-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease (LOPD)
By AskBio Inc. (AskBio) · Via GlobeNewswire · January 8, 2026
AskBio’s AB-1005 and AB-1002 Receive Pioneering Regenerative Medical Product Designation in Japan
Berlin, Germany, and Research Triangle Park, N.C., USA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Not intended for UK Media
By AskBio Inc. (AskBio) · Via GlobeNewswire · December 9, 2025
AskBio Announces Publication in Nature Medicine of 12-month data from Phase 1 Trial of AB-1002 Gene Therapy in Participants with Congestive Heart Failure
By AskBio Inc. (AskBio) · Via GlobeNewswire · October 21, 2025
AskBio Presents Interim Safety Results from Phase 1/Phase 2 LION-CS101 Clinical Trial of AB-1003 in Participants with Limb-Girdle Muscular Dystrophy 2I/R9
By AskBio Inc. (AskBio) · Via GlobeNewswire · October 10, 2025
AskBio Announces 6 Presentations at the European Society of Gene and Cell Therapy 32nd Annual Meeting
By AskBio Inc. (AskBio) · Via GlobeNewswire · October 2, 2025
First European Participants Randomized in AskBio Phase 2 Gene Therapy Trial of AB-1005 for Parkinson’s Disease
By AskBio Inc. (AskBio) · Via GlobeNewswire · September 22, 2025
AskBio Announces Completion of Enrollment in Phase 1 Clinical Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)
By AskBio Inc. (AskBio) · Via GlobeNewswire · September 17, 2025
AskBio Announces Publication of Complete Results of Phase 1b Trial of AB-1005 Gene Therapy in Participants with Parkinson’s Disease in Movement Disorders
By AskBio Inc. (AskBio) · Via GlobeNewswire · May 27, 2025
Articles from AskBio Inc. (AskBio) | The Union Democrat